Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by an increased number of circulating clonal B-cells with typical morphology and immunophenotype.¹ Accounting for 25% of all leukemias in adults, CLL is the most common leukemia in the Western world.¹ To address the clinica